Stockscreener 앱 받기
0.5426
17.79%
-0.1174
시장 영업 전:
.54
-0.0026
-0.48%
전일 마감가:
$0.66
열려 있는:
$0.6829
하루 거래량:
53.88M
Relative Volume:
9.56
시가총액:
$34.79M
수익:
-
순이익/손실:
$-51.50M
주가수익비율:
-0.1357
EPS:
-4
순현금흐름:
$-47.10M
1주 성능:
-72.60%
1개월 성능:
-73.53%
6개월 성능:
-69.52%
1년 성능:
-75.78%
1일 변동 폭
$0.5005
$0.6829
1주일 범위
$0.5005
$2.03
52주 변동 폭
$0.5005
$3.39
아웃룩 테라퓨틱스 Stock (OTLK) Company Profile
명칭
Outlook Therapeutics Inc
전화
(609) 619-3990
주소
111 S. WOOD AVENUE, ISELIN, NJ
OTLK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.5426 | 42.32M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.80 | 114.71B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.23 | 81.59B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.83 | 52.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
800.88 | 51.72B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.20 | 37.77B | 447.02M | -1.18B | -906.14M | -6.1812 |
아웃룩 테라퓨틱스 Stock (OTLK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-27 | 업그레이드 | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-08-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-13 | 개시 | CapitalOne | Overweight |
| 2023-04-03 | 개시 | Guggenheim | Buy |
| 2023-02-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-31 | 개시 | BTIG Research | Buy |
| 2022-09-13 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2019-05-16 | 개시 | Oppenheimer | Outperform |
| 2019-04-22 | 개시 | Ascendiant Capital Markets | Buy |
모두보기
아웃룩 테라퓨틱스 주식(OTLK)의 최신 뉴스
Chardan Adjusts Price Target on Outlook Therapeutics to $1 From $3, Maintains Neutral Rating - marketscreener.com
OTLK: Chardan Capital Lowers Price Target, Maintains Neutral Rat - GuruFocus
What analysts say about Outlook Therapeutics Inc stockFlag and Pennant Patterns & Double Or Triple Wealth - earlytimes.in
Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright - Investing.com Australia
Indegene Limited Included in Top Momentum ScanPortfolio Risk Assessment & Small Investment Big Gains - earlytimes.in
The Narrowing Pathway for Biotech Securities Fraud Claims: Lessons from Outlook Therapeutics - TipRanks
A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares - Stocktwits
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Lifecore Biomedical (LFCR) - The Globe and Mail
Outlook Therapeutics price target lowered to $1 from $3 at Chardan - TipRanks
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset - MSN
Outlook Therapeutics plunges 60% as FDA denies Lytenava approval | Tap to know more | Inshorts - Inshorts
Outlook Therapeutics price target lowered to 50c from $1 at H.C. Wainwright - TipRanks
Missed window? A third CRL sinks Outlook’s ONS-5010 - BioWorld MedTech
Outlook Left Adrift With Another FDA Rejection For Lytenava - Citeline News & Insights
OTLK: HC Wainwright Maintains Neutral Rating, Lowers Price Targe - GuruFocus
Regulatory tracker: Outlook Therapeutics' ophthalmic bevacizumab hit with another FDA rejection - Fierce Pharma
Outlook Therapeutics shares plunge 61.4% after US FDA declines to approve eye disease drug - marketscreener.com
What analysts say about Outlook Therapeutics Inc 41ON stockSector Leadership Analysis & Small Investment Big Gains - earlytimes.in
Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again - Sahm
Why Is Outlook Therapeutics Stock Sinking Friday?Outlook Therapeutics (NASDAQ:OTLK) - Benzinga
FDA Issues New Setback for Outlook Therapeutics’ LYTENAVA - TipRanks
Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Outlook Therapeutics Receives FDA Complete Response Letter for ONS-5010 - TradingView — Track All Markets
Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks - Investing.com
Why is Outlook Therapeutics (OTLK) Stock Down 61% in Pre-Market Trading? - TipRanks
Outlook Therapeutics plunges after FDA rejects eye drug for third time - TradingView — Track All Markets
Outlook Therapeutics plunges after rejection from the FDA - medwatch.com
Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In Focus - Benzinga
Outlook Therapeutics shares plunge 61.5% premarket after US FDA declines to approve eye disease drug - marketscreener.com
Outlook Therapeutics receives FDA response on ONS-5010 for wet AMD - Pharmaceutical Technology
VIX Spike: Can Outlook Therapeutics Inc. (41ON) stock resist broad market declines - moha.gov.vn
Apple, Taiwan Semiconductor Manufacturing And 3 Stocks To Watch Heading Into Friday - Benzinga
FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present form - Yahoo Finance
Key facts: FDA Rejects Outlook Therapeutics' Lytenava; ONS-5010 Denied Again - TradingView — Track All Markets
Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD - ts2.tech
US FDA declines to approve Outlook Therapeutics’ eye disease drug - wibqam.com
Outlook Therapeutics Shares Sink After FDA Issues Another CRL On Wet AMD Therapy - Nasdaq
FDA rejects Outlook Therapeutics’ ONS-5010 eye treatment application By Investing.com - Investing.com Nigeria
Breaking news: FDA sends CRL to Outlook Therapeutics for ONS-5010 resubmission - Optometry Times
Outlook Therapeutics provides regulatory update on U.S. FDA review of Lytenava - marketscreener.com
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA - Ophthalmology Times
US FDA declines to approve Outlook's eye disease drug for second time in 2025 - Reuters
Outlook Therapeutics slides after US FDA declines its eye disease drug - TradingView — Track All Markets
FDA rejects Outlook Therapeutics’ ONS-5010 eye treatment application - Investing.com India
Outlook Therapeutics (OTLK) Shares Plunge After FDA Setback - GuruFocus
Outlook Therapeutics (OTLK) Faces FDA Setback for Wet AMD Treatm - GuruFocus
Outlook Therapeutics Faces Challenges Amid Market Dynamics - StocksToTrade
Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date - ts2.tech
Outlook Therapeutics stock plunges after FDA rejects wet AMD drug application - Investing.com Canada
Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision - ts2.tech
Outlook Therapeutics Says FDA Didn't Approve Macular Degeneration Drug Application - marketscreener.com
아웃룩 테라퓨틱스 (OTLK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.03%
0.06%
자본화:
|
볼륨(24시간):